By otakuyassine3@gmail.com 
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) COO Peter Radovich sold 3,177 shares of the firm’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $152,241.84. Following the completion of the transaction, the chief operating officer now owns 29,588 shares of the company’s stock, valued at $1,417,856.96. The trade was a 9.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Peter Radovich also recently made the following trade(s):
- On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $85,554.36.
Mirum Pharmaceuticals Stock Performance
MIRM stock traded up $0.95 during mid-day trading on Monday, hitting $48.48. 1,319,360 shares of the company were exchanged, compared to its average volume of 540,941. The stock has a market capitalization of $2.33 billion, a PE ratio of -24.00 and a beta of 0.98. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The business has a 50 day simple moving average of $43.76 and a 200-day simple moving average of $41.61. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $49.40.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company’s revenue for the quarter was up 89.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.57) EPS. On average, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. State Street Corp lifted its stake in Mirum Pharmaceuticals by 19.9% in the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after buying an additional 297,511 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Mirum Pharmaceuticals by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock valued at $12,798,000 after acquiring an additional 17,149 shares during the period. Geode Capital Management LLC boosted its stake in Mirum Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock worth $36,519,000 after acquiring an additional 29,017 shares in the last quarter. GSA Capital Partners LLP grew its holdings in Mirum Pharmaceuticals by 791.7% in the third quarter. GSA Capital Partners LLP now owns 57,985 shares of the company’s stock worth $2,261,000 after purchasing an additional 51,482 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its stake in Mirum Pharmaceuticals by 25.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock valued at $6,021,000 after purchasing an additional 29,545 shares in the last quarter.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on MIRM shares. Citigroup upped their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Leerink Partners boosted their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $57.10.
View Our Latest Stock Analysis on Mirum Pharmaceuticals
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Featured Articles
Receive News & Ratings for Mirum Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.